Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 7:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 2,770 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: One cycle Clear all
Completed Phase 2 Interventional Results available

Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L

NCT00807599
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Stem cell transplant x 1 or x 2, lenalidomide and dexamethasone
Procedure · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 28, 2026, 7:30 PM EDT
Completed Phase 4 Interventional Results available

Olmesartan Comparison to Losartan in Hypertensive Subjects

NCT00949884
View directory record Official record
Conditions
Hypertension
Interventions
olmesartan medoxomil, Placebo, losartan potassium
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
941 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
20
States / cities
Mesa, Arizona • Phoenix, Arizona • Harbor City, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2011 · Synced Oct 28, 2026, 7:30 PM EDT
Not listed Phase 2 Interventional

Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria

NCT00916747
View directory record Official record
Conditions
Progeria
Interventions
Lonafarnib, Zoledronic Acid, and Pravastatin
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 28, 2026, 7:30 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Antibiotic Resistance and Microbiome in Children Aged 6-59 Months in Nouna, Burkina Faso

NCT03187834
View directory record Official record
Conditions
Child Development
Interventions
Azithromycin, Amoxicillin, Cotrimoxazole, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
6 Months to 59 Months
Enrollment
252 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Oct 28, 2026, 7:30 PM EDT
Completed Phase 2 Interventional

Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer

NCT00100906
View directory record Official record
Conditions
Kidney Cancer
Interventions
IL-2, ATRA
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 16, 2013 · Synced Oct 28, 2026, 7:30 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas

NCT00624416
View directory record Official record
Conditions
Lipoma
Interventions
Prednisolone synthetic cortisone and Isoproterenol together
Drug
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 28, 2026, 7:30 PM EDT
Completed Phase 2 Interventional Results available

Imexon for Relapsed Follicular and Aggressive Lymphomas

NCT01314014
View directory record Official record
Conditions
Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Burkitt's Lymphoma
Interventions
Imexon
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Tucson, Arizona • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2016 · Synced Oct 28, 2026, 7:30 PM EDT
Completed Phase 1 Interventional

Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours

NCT05043714
View directory record Official record
Conditions
Metastatic Cancer, Epithelial Tumor
Interventions
NG-641 in combination with Nivolumab
Biological
Lead sponsor
Akamis Bio
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Fullerton, California • Santa Monica, California • Celebration, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 28, 2026, 7:30 PM EDT
Recruiting Phase 1 Interventional

Venetoclax Basket Trial for High Risk Hematologic Malignancies

NCT05292664
View directory record Official record
Conditions
Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated, Treatment-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Lymphoblastic Lymphoma, in Relapse, Lymphoblastic Lymphoma, Refractory, Acute Leukemia of Ambiguous Lineage in Relapse, Acute Leukemia of Ambiguous Lineage
Interventions
Venetoclax, Azacitidine, Cytarabine, Methotrexate, Hydrocortisone, Leucovorin, Dexamethasone, Vincristine, Doxorubicin, Dexrazoxane, Calaspargase Pegol, Erwinia asparaginase
Drug
Lead sponsor
Andrew E. Place, MD
Other
Eligibility
1 Year to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
5
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 28, 2026, 7:30 PM EDT
Active, not recruiting Phase 1 Interventional

Study of E7386 in Participants With Selected Advanced Neoplasms

NCT03264664
View directory record Official record
Conditions
Advanced Neoplasms
Interventions
E7386
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
6
States / cities
Phoenix, Arizona • Los Angeles, California • Pasadena, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 28, 2026, 7:30 PM EDT
Recruiting Not applicable Interventional

Post Prandial Individual Responses to Different Foods

NCT06989164
View directory record Official record
Conditions
PreDiabetes, Diabetes Mellitus, Type 2, Healthy
Interventions
Post prandial testing
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 28, 2026, 7:30 PM EDT
Completed Not applicable Interventional Results available

Molecular-Guided Therapy for Childhood Cancer

NCT02162732
View directory record Official record
Conditions
Neuroblastoma, Medulloblastoma, Glioma, Ependymoma, Choroid Plexus Neoplasms, Craniopharyngioma, Dysembryoplastic Neuroepithelial Tumor, Meningioma, Primitive Neuroectodermal Tumors (PNETs), Germ Cell Tumors, Rhabdomyosarcoma, Non-rhabdomyosarcoma, Ewings Sarcoma, Osteosarcoma, Wilms Tumor, Renal Cell Carcinoma, Malignant Rhabdoid Tumor, Clear Cell Sarcoma, Liver Tumors
Interventions
Guided Therapy
Device
Lead sponsor
Giselle Sholler
Other
Eligibility
13 Months to 21 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
18
States / cities
Little Rock, Arkansas • San Diego, California • Hartford, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 28, 2026, 7:30 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Crinone 8% Intravaginal Gel and IM Progesterone Supplementation for In Vitro Fertilization (IVF)

NCT00656201
View directory record Official record
Conditions
Infertility
Interventions
Crinone 8% Vaginal Gel, Intramuscular Progesterone
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 39 Years · Female only
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 22, 2011 · Synced Oct 28, 2026, 7:30 PM EDT
Completed Phase 4 Interventional Results available

The Impact of Venlafaxine on Apnea Hypopnea Index in Obstructive Sleep Apnea

NCT02714400
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Venlafaxine, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2020 · Synced Oct 28, 2026, 7:30 PM EDT
Terminated Phase 1 Interventional

A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma

NCT00585000
View directory record Official record
Conditions
Melanoma
Interventions
CP-675,206
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
8
States / cities
Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 28, 2026, 7:30 PM EDT
Recruiting Not applicable Interventional

TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients

NCT05535192
View directory record Official record
Conditions
Breast Cancer, Stage III Breast Cancer, Breast Cancer Female, Stage I Breast Cancer, Stage II Breast Cancer
Interventions
THRIVE, Health Education Support Program
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
65 Years and older · Female only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Boston, Massachusetts • Cleveland, Ohio • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 28, 2026, 7:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of Antihistamines on Pre-Pulse Inhibition

NCT01537471
View directory record Official record
Conditions
Healthy
Interventions
Placebo, Meclizine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 40 Years
Enrollment
117 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 28, 2026, 7:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC

NCT02625207
View directory record Official record
Conditions
Healthy Subjects
Interventions
Maraviroc (Part 1), Maraviroc (Part 2), Darunavir/cobicistat (Part 2)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 28, 2026, 7:30 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Antipruritic Effect of Topical Ketamine, Amitriptyline, and Lidocaine

NCT03096444
View directory record Official record
Conditions
Pruritus
Interventions
Ketamine Hydrochloride, Amitriptyline Hydrochloride, Lidocaine Hydrochloride, Ketamine hydrochloride, Amitriptyline hydrochloride, and Lidocaine hydrochloride, Lipoderm Cream
Drug · Combination Product
Lead sponsor
Gil Yosipovitch
Other
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 28, 2026, 7:30 PM EDT
Completed Not applicable Interventional Results available

Myocardial Stress Perfusion Imaging With Dual Source CT

NCT00853671
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Adenosine Stress Dual-source CTP
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 17, 2018 · Synced Oct 28, 2026, 7:30 PM EDT
Completed Not applicable Interventional

Cancer Financial Experience

NCT05018000
View directory record Official record
Conditions
Cancer
Interventions
Financial navigation, Enhanced usual care
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 28, 2026, 7:30 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma

NCT00923936
View directory record Official record
Conditions
Sarcoma, Kaposi
Interventions
Liposomal Doxorubicin, Bevacizumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 28, 2026, 7:30 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Metformin and Polysorbate 80 on Drug Absorption and Disposition

NCT04640571
View directory record Official record
Conditions
Bile Salt Export Pump (BSEP) Transporter, Polysorbate 80
Interventions
pravastatin and chenodeoxycholic acid, after metformin and placebo, valacyclovir, chenodeoxycholic acid, and enalaprilat, after polysorbate 80 and placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Oct 28, 2026, 7:30 PM EDT
Terminated Phase 1 Interventional

Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

NCT06158100
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Venetoclax, Azacitidine, Donor Lymphocyte Infusion
Drug · Biological
Lead sponsor
Antonio M Jimenez Jimenez
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 28, 2026, 7:30 PM EDT